Abstract
We compared the efficacies of liposomal amphotericin B (LAmB) and an amphotericin B lipid complex (ABLC) in diabetic ketoacidotic (DKA) or neutropenic mice with disseminated zygomycosis. ABLC was as effective as LAmB in neutropenic but not DKA mice. Low-dose ABLC was less effective than LAmB at reducing brain fungal burdens in both models.
Publication types
-
Comparative Study
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amphotericin B / administration & dosage
-
Amphotericin B / therapeutic use*
-
Animals
-
Antifungal Agents / administration & dosage
-
Antifungal Agents / therapeutic use*
-
Diabetic Ketoacidosis / complications
-
Disease Models, Animal*
-
Drug Combinations
-
Humans
-
Liposomes / administration & dosage
-
Liposomes / therapeutic use*
-
Male
-
Mice
-
Mice, Inbred BALB C
-
Neutropenia / complications
-
Phosphatidylcholines / administration & dosage
-
Phosphatidylcholines / therapeutic use*
-
Phosphatidylglycerols / administration & dosage
-
Phosphatidylglycerols / therapeutic use*
-
Rhizopus / drug effects
-
Rhizopus / pathogenicity
-
Treatment Outcome
-
Zygomycosis / drug therapy*
-
Zygomycosis / microbiology
-
Zygomycosis / mortality
Substances
-
Antifungal Agents
-
Drug Combinations
-
Liposomes
-
Phosphatidylcholines
-
Phosphatidylglycerols
-
liposomal amphotericin B
-
Amphotericin B